

# 20 years of improving life for women through research



Improving life for  
women through  
cancer research

## ANNUAL REPORT SUMMARY 2020

To view the full online Annual Report, please visit

[WWW.ANZGOG.ORG.AU/ANNUAL-REPORT-2020](http://WWW.ANZGOG.ORG.AU/ANNUAL-REPORT-2020)

# GYNAECOLOGICAL CANCER

Gynaecological cancers originate in female reproductive organs. The main types of gynaecological cancers are ovarian, uterine, and cervical. Other types are vulvar, vaginal, fallopian tube, and rarer pregnancy-related cancers.

There is no single test for gynaecological cancers, only the cervical screening test (formerly known as the PAP test). Diagnosis is made via blood tests, scans and biopsy.

Every day in Australia **18**



**WOMEN** are diagnosed with a **GYNAECOLOGICAL CANCER**

APPROX **340 NZ WOMEN** are **DIAGNOSED** with **OVARIAN CANCER EVERY YEAR**

DESPITE CERVICAL CANCER BEING THE ONLY GYNAECOLOGICAL CANCER TO HAVE A SCREENING TEST,

**933 WOMEN** WERE ESTIMATED TO BE DIAGNOSED WITH CERVICAL CANCER IN 2020

While **SURVIVAL ACROSS ALL CANCERS** has **IMPROVED** by **19%** over the past 25 years, **SURVIVAL FOR GYNAECOLOGICAL CANCERS IMPROVED BY JUST 7%.**

Material sourced from Australian Institute of Health and Welfare and the New Zealand Ministry of Health.



Estimated number of **DEATHS** from **GYNAECOLOGICAL CANCER** in 2020 **2,096 FEMALES**



of **AUSTRALIAN WOMEN**



of **NEW ZEALAND WOMEN**

with **OVARIAN CANCER** will **SURVIVE 5 YEARS** from diagnosis



**ENDOMETRIAL CANCER** incidence has risen in the last **10 YEARS**, **55%** with obesity being a key factor.



# WHO WE ARE

The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is the peak national gynaecological cancer research organisation for Australia and New Zealand. ANZGOG has over 1060 members representing clinical, allied health and pure research specialities. ANZGOG clinical trials are conducted at 59 hospital sites and include both local and global collaborations to ensure the best research is available for women. Our purpose is to improve the outcomes and quality of life for women with gynaecological cancers through conducting and promoting cooperative clinical trials and undertaking multidisciplinary research into causes, prevention and treatments of gynaecological cancer.

## OUR BOARD OF DIRECTORS

AS AT JUNE 30 2020

- Assoc Prof Philip Beale (ANZGOG Chair)
- Assoc Prof Alison Brand
- Dr Alison Davis
- Prof Clare Scott
- Mr David Rogers
- Prof Linda Mileschkin
- Dr Michelle Wilson (NZ Director)
- Dr Paul Cohen
- Dr Pearly Khaw
- Ms Rachael Sutton
- Assoc Prof Tarek Meniawy
- Ms Wanda Lawson

## OUR STAFF

AS AT JUNE 30 2020

- Alison Evans - Chief Executive Officer
- John Andrews - Research
- Roxanne Parungao - Research
- Claire Davies - TR-ANZGOG
- Karen Livingstone AM - Fundraising
- Ella Meehan - Fundraising
- Louise Ward - Fundraising
- Dr Helen Gooden - Survivors Teaching Students
- George Gill - Communications
- Heshani Nesfield - Membership and Committees
- Preeti Highmoor - Database
- Ursula Walters - Finance
- Gina Hunt - Finance
- Elise Ackland - Admin
- Kylie Tattersall - Admin (Maternity Leave)



**ASSOC PROF PHILIP BEALE**  
Chair - ANZGOG

“ IN THE LAST 20 YEARS ANZGOG HAS ENABLED 60 STUDIES, INCLUDING 37 CLINICAL TRIALS, TREATING CLOSE TO 4,000 PATIENTS. WE ARE VERY POSITIVE ABOUT THE CONTRIBUTION THAT ANZGOG AND ITS MEMBERS CAN MAKE TO THE FUTURE OF GYNAECOLOGICAL CANCER RESEARCH BOTH HERE IN AUSTRALIA AND NEW ZEALAND AND INTERNATIONALLY. ”

## OUR STRATEGIC GOALS

The Board of Directors conducts a strategic planning workshop every five years in consultation with member representatives of all gynaecological oncology disciplines, cancer consumers and other key stakeholders. The identified strategic goals form the basis of the business plan which is developed and reviewed annually.

### DEMONSTRATING LEADERSHIP IN GYNAECOLOGICAL CANCER RESEARCH

We demonstrate leadership in investigator-led gynaecological cancer clinical research in Australia and New Zealand by actively sharing our learnings to improve clinical and research practice and working to drive excellence in Australian and New Zealand clinical research.

### ANZGOG'S FIVE KEY STRATEGIC GOALS FOR 2018-2023 ARE TO HAVE:

#### 1 - Innovative & equitable clinical trials in gynaecological cancers.

We will actively facilitate a collaborative clinical trials agenda that considers priority questions for all gynaecological cancers and reflects the diverse needs of women in Australia and New Zealand.

#### 2 - World-class translational research in gynaecological cancers.

We will implement and embed TR-ANZGOG, driving world-class translational research in gynaecological cancers.

#### 3 - Capacity building for gynaecological cancer research in Australia and New Zealand.

We will build the capacity of the clinical research and gynaecological cancer community in Australia and New Zealand to undertake and participate in practice-changing research in gynaecological cancers.

#### 4 - Strategic partnerships, collaboration & engagement.

We will actively engage with our members, the Australian and New Zealand clinical research community and our international partners to ensure the relevance, vibrancy and impact of our research agenda.


#### 5 - Organisational capacity aligned with our research agenda.

We will develop further maturity in our organisational capability and financial sustainability to support our gynaecological cancer research goals in an efficient and streamlined manner.

2020 HAS BEEN A GOOD YEAR FOR ANZGOG'S RESEARCH PORTFOLIO, ALTHOUGH DEFINITELY CHALLENGING AT TIMES. ANZGOG'S COVID-19 RESPONSE WAS SWIFT AND MEASURED. WE WOULD LIKE TO THANK OUR RESEARCH TEAMS FOR THEIR CONTRIBUTION TO THE EFFECTIVE MANAGEMENT OF ALL OUR TRIALS TO ENSURE THE SAFETY AND WELLBEING OF THE WOMEN PARTICIPATING.

**ASSOC PROF PHILIP BEALE**  
Chair - ANZGOG

## SUMMARY OF ACHIEVEMENTS – 2019-2020



## CLINICAL TRIALS


“ANZGOG’S RECRUITING TRIAL PORTFOLIO IS CURRENTLY LARGER THAN IT EVER HAS BEEN BEFORE. OUR PORTFOLIO COVERS A WIDE RANGE OF THERAPIES, INCLUDING IMMUNOTHERAPY, CHEMOTHERAPY, SURGICAL INTERVENTIONS, EXERCISE INTERVENTIONS AND OUR FIRST EVER PREVENTATIVE STUDY, STICS AND STONES. ANZGOG’S PROGRAM OF TRIALS IS FURTHER COMPLEMENTED BY THE WIDE VARIETY OF SUPPORTIVE CARE RESEARCH CURRENTLY BEING DEVELOPED IN OUR RESEARCH PIPELINE.

**DR ALISON DAVIS**

Chair - Research Advisory Committee

As at June 30 2020:

11 TRIALS OPEN TO RECRUITMENT:



## FUND FOR NEW RESEARCH

The Fund for New Research grants program fosters innovative new research ideas that aim to lead to investigator-led clinical trials. In 2019 - 2020 grant applications were received for both pre-clinical and pilot or small clinical trials.

Individual grants are awarded annually to researchers for amounts of \$50,000, \$30,000 and \$20,000. The Fund for New Research is made possible by public donations, bequests and philanthropic grants from charities with shared interests in ANZGOG’s research work. With this support we have been able to support 14 innovative new studies from 2015 to 2019 inclusive.

[WWW.ANZGOG.ORG.AU/RESEARCH/FUND-FOR-NEW-RESEARCH/](http://WWW.ANZGOG.ORG.AU/RESEARCH/FUND-FOR-NEW-RESEARCH/)

## OASIS INITIATIVE



The OASIS Initiative undertakes signal seeking Phase II clinical trials that match targeted new drug therapies with molecular subtypes of ovarian cancer, seeking evidence of clinical response to treatment which could rapidly translate to changes in treatment practice for women.

The OASIS Initiative aims to significantly shorten the cycle of clinical testing by:

**Speeding Translation:** Strengthen existing links between laboratory and clinical researchers to accelerate the application of research findings,

**Improving cost-efficiency:** Develop an infrastructure and culture that enables more cost-effective trials,

**Encouraging funding:** Establish a pool of funds including philanthropy and pharma, with proper governance oversight, to support the prompt initiation of signal-seeking studies once indicators are identified in the lab.

[WWW.ANZGOG.ORG.AU/RESEARCH/OASIS-INITIATIVE/](http://WWW.ANZGOG.ORG.AU/RESEARCH/OASIS-INITIATIVE/)

“A SIGNAL-SEEKING CLINICAL TRIAL IS LIKE SENDING OUT A SCOUTING PARTY TO MAP THE TERRAIN AHEAD. THESE TRIALS ARE NIMBLE AND RESPONSIVE TO NEW INFORMATION, SHOWING THE WAY FORWARD FOR THE MAIN GROUP.

**PROF MICHAEL FRIEDLANDER AM**

Chair - OASIS Steering Committee

## TR-ANZGOG

TR-ANZGOG is a world-class translational research initiative designed to add value to ANZGOG clinical trials for women with gynaecological cancers. TR-ANZGOG supports the collection and use of biospecimens from ANZGOG trials for further research. One of TR-ANZGOG’s goals is to help find biomarkers that are associated with good response to trial drugs, and, if response is not as good as expected, to find out why.

[WWW.ANZGOG.ORG.AU/RESEARCH/TR-ANZGOG/](http://WWW.ANZGOG.ORG.AU/RESEARCH/TR-ANZGOG/)

“TRANSLATIONAL RESEARCH IS NOW FRONT AND CENTRE OF MANY CANCER CLINICAL TRIALS. TR-ANZGOG AIMS TO SUPPORT TRIAL INVESTIGATORS TO ACHIEVE THEIR TRANSLATIONAL AIMS, AND TO SUPPORT CURRENT AND FUTURE RESEARCH THAT WILL IMPROVE OUTCOMES FOR WOMEN WITH GYNAECOLOGICAL CANCER.

**PROF ANNA DEFAZIO**

Chair - TR-ANZGOG Steering Committee



## COLLABORATION & ENGAGEMENT

We actively engage with our members in the Australian and New Zealand clinical research community and our international partners to ensure the relevance, vibrancy and impact of our research agenda. This includes active participation from the next generation of gynaecological cancer researchers and continuing to foster effective two-way communication with cancer consumers.


### INTERNATIONAL COLLABORATIONS

ANZGOG's international collaborations are fostered through its individual members and organisational membership of the Gynecologic Cancer InterGroup with 32 member countries. ANZGOG participated in the formation of the Asia Pacific Gynecological Oncology Trials group (APGOT) in November 2019. APGOT was formed to focus on collaborative studies in gynaecological cancer within the Asia Pacific region, strengthening capabilities and ensuring a greater range of trials are available for women.



ANZGOG Members met at the 2019 Research Development Day to discuss and develop the latest research concepts.

### SURVIVORS TEACHING STUDENTS



Survivors Teaching Students (STS) is a ground-breaking volunteer program that brings the faces and voices of ovarian cancer survivors and caregivers into the classrooms of health professional students to educate them about women's experiences with the disease.

Uninterrupted by the COVID-19 lockdown, STS volunteer teams around Australia have continued sharing their stories virtually (via Zoom), raising awareness of ovarian cancer and promoting the importance of good health communication.

“ THE UNIVERSITIES WE WORK WITH HOLD ANZGOG'S STS PROGRAM IN HIGH REGARD AND DID NOT WANT THE STUDENTS TO MISS OUT ON THE OPPORTUNITY TO PARTICIPATE IN THE PROGRAM. IN 2020, 33 PRESENTATIONS WERE HELD, REACHING 1641 STUDENTS. ”

**DR HELEN GOODEN**  
STS National Program Manager

The program is now working with 15 universities across 5 states - NSW, VIC, QLD, WA and SA - engaging over 3,000 students in education sessions delivered by over 100+ trained volunteers.

### LOCAL COLLABORATIONS

Strong local collaborations are fostered with institutions such as Sydney and Melbourne Universities, Walter & Eliza Hall Research Institute, QIMR Berghofer Medical Research Institute, Queensland University of Technology and University of Western Australia are ensuring a diverse approach to research ideas and clinical trial development.

### ENGAGING WOMEN IN RESEARCH

“ THE ANZGOG CONSUMER RESEARCH PANEL (CRP) IS THE MECHANISM FOR ADVICE AND INPUT FROM GYNAECOLOGICAL CANCER SURVIVORS AND THEIR CARERS TO THE RESEARCH ADVISORY COMMITTEE, TUMOUR TYPE WORKING GROUPS, BOARD OF DIRECTORS AND MEMBERS. THE PANEL HELPS ANZGOG TO EFFECTIVELY REPRESENT THE NEEDS AND EXPECTATIONS OF GYNAECOLOGICAL CANCER CONSUMERS AND HELPS SET GENERAL RESEARCH DIRECTIONS AND PRIORITIES AND SHAPE RESEARCH FOR ANZGOG. ”

**WANDA LAWSON**  
Chair - Consumer Research Panel





## PHILANTHROPY & FUNDRAISING

### FUNDING RARE CANCER RESEARCH



Diagnosed with leiomyosarcoma, a rare type of cancer that affects smooth muscle tissue (most commonly in the abdomen but can occur anywhere in the body), Rochelle Fisher wanted to take direct action to assist other women diagnosed with a rare endometrial cancer by raising funds to support a Fund for New Research grant for a pre-clinical or pilot study that could break new ground in finding solutions. Rochelle sent out a link to her GoFundMe page to supportive family and friends as well as hosting an information night with ANZGOG Founder, Prof Michael Friedlander AM, speaking about research. She raised \$33,500 towards a leiomyosarcoma pre-clinical project and continues to develop new fundraising activities to raise funds for further studies. Thank you Rochelle for an outstanding contribution.

### CURE OUR OVARIAN CANCER



In 2017, when Jane Ludemann was diagnosed with low grade serous ovarian cancer (LGSOC) at 33 years of age, she had never heard of the disease. There wasn't any dedicated research on her subtype of cancer, so she founded a charity (Cure Our Ovarian Cancer) and created partnerships with research organisations around the world. ANZGOG is the chosen recipient of research funding for low grade serous ovarian cancer research in Australia. People affected by LGSOC in Australia are now raising valuable funds for ANZGOG's research program.

### THE LADYBIRD FOUNDATION



The Ladybird Foundation Grant is a \$30,000 grant offered to a project which is primarily carried out in Western Australia with a WA Principal Investigator. In the 2019 Fund for New Research grant round, Dr Paul Cohen was awarded this grant for his study - Getting the MOST out of ovarian cancer follow-up. This pilot study will investigate a novel approach to the follow-up of women with ovarian cancer after completion of surgery and chemotherapy.

### ANZGOG'S PRE-CLINICAL STUDY RECEIVES PERPETUAL GRANT FUNDING



ANZGOG Member Assoc Prof Pamela Pollock's pre-clinical endometrial cancer study was awarded Perpetual grant funding in June 2020. "I am super excited to receive this funding as it will allow me to validate our findings in samples from an international clinical trial (PORTEC-3) that ANZGOG was involved in testing whether the addition of chemotherapy to standard radiation was beneficial in patients at high risk of recurrence." said Assoc Prof Pollock. "If we can show patients with this variant form do not respond to radiation and chemotherapy this will help generate evidence to test a new class of drug (FGFR inhibitors) in patients diagnosed with high-risk endometrial cancer."



**WomenCan engages the community to fund pioneering discoveries by ANZGOG that will enable women with a gynaecological cancer to live longer, better lives.**

**We have seen first-hand how strong, determined and courageous women are in the face of a life-threatening disease. We believe that WomenCan be even stronger with you, the community, by their side.**

**WomenCan was borne out of the merger of ANZGOG and Women's Cancer Foundation to make a real difference in the lives of women with gynaecological cancers.**

Fundraising for cancer research is achieved through initiatives like 'Save the Box' – an awareness and community fundraising program held each September during Gynaecological Cancer Awareness Month, and 'Team Teal' – a partnership fundraising and awareness program undertaken with the harness racing industry in Australia and New Zealand during Ovarian Cancer Awareness Month in February.

There are many ways to get involved with WomenCan and support innovative new research with ANZGOG's Fund for New Research Grant program, and Survivors Teaching Students which helps foster greater awareness of gynaecological cancer with trainee medical practitioners, and to help support major research initiatives such as OASIS and TR-ANZGOG, both world-class research programs.

Head of Fundraising and Development, Karen Livingstone AM, is keen to reach out to individuals, groups and organisations who would like to get involved in activities that will help women with a gynaecological cancer live longer, better lives.

Karen Livingstone AM E: [development@anzgog.org.au](mailto:development@anzgog.org.au) T: 0438 11 55 24


[womenscan.org.au](http://womenscan.org.au)




## OUR MEMBERSHIP

Our membership has grown significantly since our organisation was founded in 2000, doubling in the last seven years to over 1,000. ANZGOG's members are in every Australian state and New Zealand and are dedicated to growing the research portfolio in both treatment, surgery, radiation oncology, quality of life and survivorship. Together with our staff, donors and partners, our members work to improve life for women through cancer research.

### MEMBERSHIP GROWTH 2010 - 2020:



### GROUPED BY PROFESSIONAL FIELD



## FUNDING OUR RESEARCH

ANZGOG continues to grow funding for clinical trials through grants and pharma support, engaging with our many and valued supporters to raise funds through donations and philanthropy, and growing the organisation in a balanced and thoughtful way to support our research agenda. In addition to research conducted directly by ANZGOG, through our collaboration with the University of Sydney over the last 20 years and its NHMRC Clinical Trials Centre, we have been able to support a further \$23,500,425 of collaborative research.


## STATEMENT OF FINANCIAL POSITION

YEAR ENDING JUNE 30 2020



ASSETS	2020 \$	2019 \$
Total current assets	2,052,671	2,575,374
Total non-current assets	4,503,615	4,644,330
<b>TOTAL ASSETS</b>	<b>6,556,286</b>	<b>7,219,704</b>
<b>LIABILITIES</b>		
Total current liabilities	2,185,428	2,148,884
Total non-current liabilities	17,760	-
<b>TOTAL LIABILITIES</b>	<b>2,203,188</b>	<b>2,148,884</b>
<b>NET ASSETS</b>	<b>4,353,098</b>	<b>5,070,820</b>
<b>EQUITY</b>		
New Research Fund Reserve	259,041	397,150
Beneficiary Fund Reserve	339,717	209,267
OASIS Initiative Reserve	2,009,116	1,864,407
Retained Surplus	1,745,224	2,599,996
<b>TOTAL EQUITY</b>	<b>4,353,098</b>	<b>5,070,820</b>

In 2020, ANZGOG applied \$235,231 of its reserves to Research Projects. It also accounted for a net change in fair value of its investments of \$343,551 due to COVID-19 impacts.


## INCREASED SPEND ON RESEARCH & EDUCATION



## INCOME & EXPENSES



## TOTAL EQUITY INCLUDING PROJECT RESERVES



View the full Annual Financial Report for the year ending 30 June 2020, audited by BDO East Coast Partnership at: [www.anzdog.org.au/wp-content/uploads/2020/10/ANZGOG-Annual-Financial-Report-2020.pdf](http://www.anzdog.org.au/wp-content/uploads/2020/10/ANZGOG-Annual-Financial-Report-2020.pdf)



## CURRENT CLINICAL TRIALS - OPEN TO RECRUITMENT

AS AT JUNE 30 2020:

TRIAL	TITLE	CANCER TYPE	PRINCIPAL INVESTIGATOR	CONTACT
1 ECHO	A Phase III randomised, controlled trial of exercise during chemotherapy for patients commencing first line treatment for ovarian cancer	OVARIAN	Prof Sandi Hayes	echo@ctc.usyd.edu.au
2 ICON9	An international Phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy	OVARIAN	Prof Linda Mileschkin	icon9@ctc.usyd.edu.au
3 SOLACE2	A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects	OVARIAN	Prof Clare Scott Assoc Prof Chee Lee (Co-Chair) Prof Michael Friedlander AM (Co-Chair) Prof Magdalena Plebanski (Translational Chair)	solace2@ctc.usyd.edu.au
4 EMBRACE	A Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2	OVARIAN	Dr Katrin Sjoquist	embrace@ctc.usyd.edu.au
5 iPRIME	A Phase II study of durvalumab (MEDI14736) and tremelimumab in combination with neoadjuvant carboplatin and paclitaxel in newly diagnosed women with advanced stage high grade serous ovarian, fallopian tube and peritoneal cancers	OVARIAN	Assoc Prof Tarek Meniawy	trials@anzgog.org.au
6 VIP	A Phase II study of intravenous vinorelbine in patients with relapsed platinum resistant or refractory C5 high grade serous, endometrioid, or undifferentiated primary peritoneum, fallopian tube or ovarian cancer	OVARIAN	Prof Linda Mileschkin	trials@anzgog.org.au
7 STICs and STONES	A randomised Phase II double-blind placebo-controlled trial of acetylsalicylic acid (Aspirin) for prevention of ovarian cancer in women with BRCA1 and BRCA2 mutations	OVARIAN	Prof Kelly-Anne Phillips	stics@ctc.usyd.edu.au
8 TIPS	Testing Individual Interventions to Optimize Perioperative Care in Ovarian Cancer Surgery	OVARIAN	Assoc Prof Alison Brand	tips@ctc.usyd.edu.au
9 PRECISE	A Phase II, signal-seeking trial of the clinical benefit rate associated with pamiparib in subjects with germline or somatic BRCA1/2 high grade serous ovarian cancer or carcinosarcoma who have progressed on P-gp substrate chemotherapy or PARP inhibitors with the presence of an ABCB1 fusion and the absence of a BRCA1/2 reversion	OVARIAN	Dr Ali Freimund	trials@anzgog.org.au
10 IGNITE	A Phase II signal-seeking trial of adavosertib (AZD1775) targeting recurrent high grade serous ovarian cancer (HGSC) with cyclin E1 (CCNE1) over-expression with and without gene amplification	OVARIAN	Dr George Au-Yeung	trials@anzgog.org.au
11 EmQUEST	Identifying factors which predict for health-related quality of life deficits and increased symptom burden in women who have been treated for endometrial cancer	ENDOMETRIAL	Prof Linda Mileschkin	Nikki.Burdett@petermac.org

Note - 11 trials open to recruitment, 4 trials in start-up and 3 trials closed to recruitment. Total of 18 trials in FY2019-2020.

## PARTICIPATING SITES

FROM JULY 1 2019 TO JUNE 30 2020:

	IGNITE	PRECISE	ECHO	EXCISE	STICS	SOLACE2	TIPS	ICON9	EMBRACE	VIP	MOCCA	iPRIME
QLD	Gold Coast University Hospital											
	Greenslopes Private Hospital			◆								
	ICON Cancer Care							◆	◆			
	Mater Adult Hospital	-	-	◆		◆		◆		-		◆
	Mater Private Hospital											
	Nambour General Hospital											
	Pindara Private Hospital							◆	◆			
	Qld Centre for Gynaecological Cancer Research			◆								
	Royal Brisbane and Women's Hospital			◆				◆	◆		◆	◆
	The Townsville Hospital							◆		◆		
	Toowoomba Hospital											
	The Wesley Hospital			◆								
	Calvary Mater Newcastle		◆						◆			
	Campbelltown Hospital			◆								
NSW	Coffs Harbour Health Campus					◆			◆			
	Gosford Hospital					◆		◆				
	John Hunter Hospital						◆					
	Lismore Base Hospital											
	Liverpool Hospital											
	Lake Macquarie Private Hospital											
	Macarthur Cancer Care Centre		-					◆				
	Newcastle Private Hospital					◆						◆
	Orange Base Hospital	-										
	Port Macquarie Base Hospital											
	Prince of Wales Hospital	◆	◆			◆	◆	◆		◆	◆	◆
	Riverina Cancer Centre						◆					
	Royal Hospital for Women	◆	◆			◆	◆	◆		◆	◆	◆
	Royal Prince Alfred Hospital	-		-		◆		-				
	Chris O'Brien Lifehouse											
	Royal North Shore Hospital					◆			◆			
	St George Hospital					◆			◆			◆
	Tweed Hospital					◆						
Wollongong Hospital												
Westmead Hospital	-		◆	◆	◆		◆	◆			◆	

	IGNITE	PRECISE	ECHO	EXCISE	STICS	SOLACE2	TIPS	ICON9	EMBRACE	VIP	MOCCA	iPRIME	
ACT	Canberra Hospital		◆					◆					
	Ballarat Base Hospital								-				
VIC	Border Medical Oncology							◆	◆	◆			
	Box Hill Hospital											◆	
	Frankston Hospital						◆						
	Monash Medical Centre - Clayton		◆					◆				◆	
	Peter MacCallum Cancer Centre	◆	◆			◆	◆	◆	◆	◆	◆	◆	
	Royal Melbourne Hospital					◆							
	Sunshine Hospital	-											
	The Royal Women's Hospital			◆	◆	◆		◆					
	TAS	Hobart Private Hospital											
		Launceston Base Hospital											
Royal Hobart Hospital		◆					◆	◆					
SA	Flinders Medical Centre	-				◆		◆					
	Royal Adelaide Hospital					◆			◆				
WA	The Queen Elizabeth Hospital												
	Fiona Stanley Hospital								◆				
	Hollywood Private Hospital												
	King Edward Memorial Hospital												
	Linear Clinical Research											◆	
	Sir Charles Gairdner Hospital	-	◆								-		
NZ	St John of God Hospital, Subiaco					◆						◆	
	St John of God Hospital, Murdoch												
	Auckland Hospital								◆				
	Christchurch Hospital								◆	◆			
	Wellington Hospital												
	National Womens Health												
	Auckland City Hospital												

◆ Site currently open to recruitment  
 - Site selected but not yet open



Improving life for  
women through  
cancer research

The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is the peak national gynaecological cancer research organisation for Australia and New Zealand. We are recognised as a world leader and collaborative partner in clinical trials research.

The Australian Business Number (ABN) is 69 138 649 028.


The Australian Company Number (ACN) is 138 649 028.

ANZGOG is an Australian public company limited by guarantee. ANZGOG is endorsed as a deductible gift recipient under Section 30-15 of the Income Tax Assessment Act 1997.



WomenCan is a trading name of ANZGOG and conducts fundraising for ANZGOG's research, awareness and education activities.

**ANZGOG.ORG.AU** **WOMENCAN.ORG.AU**

 @WomenCanFund  @anzgog  @WomenCanFundraising